Novo Nordisk's stock has fallen about 70%, trading at roughly 10 times trailing earnings, presenting a buying opportunity. Despite setbacks in pricing and clinical trials, the company's promising drug pipeline, including high-dose Wegovy and other candidates, positions it favorably against competitors like Eli Lilly. The stable revenue outlook and potential price-to-earnings re-rating support expectations of mid-teens annualized returns through 2030. Risks include further clinical failures and government pricing actions, but current market pessimism may undervalue the company's long-term potential.
Deutsche Bank maintains a 'hold' rating on Novo Nordisk with a price target of DKK290 after discussions with the company's head of R&D. Novo Nordisk is cautiously optimistic about its new obesity drug study, cagrisema RD11, which may outperform the p...
Eli Lilly's Mounjaro drug revenue surged 125% to $8.66 billion last quarter, prompting a raised full-year revenue forecast of $82-$85 billion and a market cap near $882 billion. Despite this, shares have already climbed significantly, making further ...
Novo Nordisk initiated a share repurchase program on May 6, 2026, aiming to buy back up to DKK 15 billion worth of B shares over 12 months starting February 4, 2026. As of May 13, 2026, the company has repurchased nearly 16 million B shares at an ave...
Novo Nordisk's oral weight-loss drug Wegovy continues to outperform Eli Lilly's Zepbound in the US market, with about 137,000 prescriptions in its 18th week, despite a 4% weekly decline. Citi notes that actual sales may be higher due to incomplete da...
Novo Nordisk is preparing to launch its Wegovy weight-loss pill outside the U.S. later this year, targeting major international markets like the UK, Germany, and Denmark. The company sees a significant opportunity to expand globally, leveraging teleh...
